Search research articles
Contact Us
Filters
Showing results (11-20 of 39) with videos related to
Page
of 4
Sort By:
Cancer
|
June 16, 2004
Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma
Athanasios Anagnostopoulos, Ana Aleman, Gregory Ayers, et al.
Nurse Educator
|
August 4, 2015
Student Perception of Improvement in Communication and Value in 2 Interprofessional Education Delivery Formats
Ashley Arentsen, Darlene Welsh, Mikael Jones, et al.
Seminars in Oncology
|
April 30, 2003
Uniform response criteria in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia
Donna Weber, Steven P Treon, Christos Emmanouilides, et al.
Leukemia & Lymphoma
|
August 23, 2006
Risk factors for relapse after complete remission with high-dose therapy for multiple myeloma
Muzaffar H Qazilbash, Rima M Saliba, Ana Aleman, et al.
Cancer
|
February 9, 2008
Symptom burden after autologous stem cell transplantation for multiple myeloma
Erica Campagnaro, Rima Saliba, Sergio Giralt, et al.
International Journal of Hematology
|
July 4, 2012
Lenalidomide in combination with dexamethasone improves survival and time-to-progression in patients ≥65 years old with relapsed or refractory multiple myeloma
Asher A Chanan-Khan, Sagar Lonial, Donna Weber, et al.
Leukemia & Lymphoma
|
May 27, 2004
High-dose topotecan, melphalan and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of multiple myeloma
Michele L Donato, Ana Aleman, Richard E Champlin, et al.
Blood
|
April 9, 2004
Nuclear factor-kappaB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis
Alok C Bharti, Shishir Shishodia, James M Reuben, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 11, 2009
Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high-dose dexamethasone
Maurizio Zangari, Guido Tricot, Latha Polavaram, et al.
Leukemia & Lymphoma
|
September 20, 2018
Carfilzomib-based combination regimens are highly effective frontline therapies for multiple myeloma and Waldenström's macroglobulinemia
Maria Chaudhry, Raphael Steiner, Catherine Claussen, et al.
Page
of 4
Search research articles
Search
Showing results (11-20 of 39) with videos related to
Sort By:
Page
of 4
Cancer
|
June 16, 2004
Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma
Athanasios Anagnostopoulos, Ana Aleman, Gregory Ayers, et al.
Nurse Educator
|
August 4, 2015
Student Perception of Improvement in Communication and Value in 2 Interprofessional Education Delivery Formats
Ashley Arentsen, Darlene Welsh, Mikael Jones, et al.
Seminars in Oncology
|
April 30, 2003
Uniform response criteria in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia
Donna Weber, Steven P Treon, Christos Emmanouilides, et al.
Leukemia & Lymphoma
|
August 23, 2006
Risk factors for relapse after complete remission with high-dose therapy for multiple myeloma
Muzaffar H Qazilbash, Rima M Saliba, Ana Aleman, et al.
Cancer
|
February 9, 2008
Symptom burden after autologous stem cell transplantation for multiple myeloma
Erica Campagnaro, Rima Saliba, Sergio Giralt, et al.
International Journal of Hematology
|
July 4, 2012
Lenalidomide in combination with dexamethasone improves survival and time-to-progression in patients ≥65 years old with relapsed or refractory multiple myeloma
Asher A Chanan-Khan, Sagar Lonial, Donna Weber, et al.
Leukemia & Lymphoma
|
May 27, 2004
High-dose topotecan, melphalan and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of multiple myeloma
Michele L Donato, Ana Aleman, Richard E Champlin, et al.
Blood
|
April 9, 2004
Nuclear factor-kappaB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis
Alok C Bharti, Shishir Shishodia, James M Reuben, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 11, 2009
Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high-dose dexamethasone
Maurizio Zangari, Guido Tricot, Latha Polavaram, et al.
Leukemia & Lymphoma
|
September 20, 2018
Carfilzomib-based combination regimens are highly effective frontline therapies for multiple myeloma and Waldenström's macroglobulinemia
Maria Chaudhry, Raphael Steiner, Catherine Claussen, et al.
Page
of 4